These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1284508)

  • 1. [Advances in AIDS vaccines].
    Piédrola Angulo G
    An R Acad Nac Med (Madr); 1992; 109(3):531-50. PubMed ID: 1284508
    [No Abstract]   [Full Text] [Related]  

  • 2. India targets local HIV strain in test of AIDS vaccine.
    Jayaraman KS
    Nature; 2004 Jan; 427(6971):185. PubMed ID: 14724601
    [No Abstract]   [Full Text] [Related]  

  • 3. Induction of HIV-1-specific neutralizing antibodies in mice vaccinated with a recombinant Sendai virus vector.
    Kano M; Matano T; Kato A; Shioda T; Nagai Y
    Jpn J Infect Dis; 2002 Apr; 55(2):59-60. PubMed ID: 12082313
    [No Abstract]   [Full Text] [Related]  

  • 4. Neutralizing epitopes in the membrane-proximal region of HIV-1 gp41: genetic variability and co-variation.
    Dong XN; Chen YH
    Immunol Lett; 2006 Aug; 106(2):180-6. PubMed ID: 16859756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes: advances in 1994-1995.
    Berzofsky JA; Berkower IJ
    AIDS; 1995; 9 Suppl A():S143-57. PubMed ID: 8819581
    [No Abstract]   [Full Text] [Related]  

  • 6. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.
    Lorin C; Delebecque F; Labrousse V; Da Silva L; Lemonnier F; Brahic M; Tangy F
    Vaccine; 2005 Aug; 23(36):4463-72. PubMed ID: 15993518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on HIV vaccines.
    Meldorf M; Corey L
    STEP Perspect; 1997; 9(2):5-6, 8-9. PubMed ID: 11364929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AIDS/HIV. A STEP into darkness or light?
    Moore JP; Klasse PJ; Dolan MJ; Ahuja SK
    Science; 2008 May; 320(5877):753-5. PubMed ID: 18467578
    [No Abstract]   [Full Text] [Related]  

  • 9. [Immunization against HIV. Problems in developing a vaccine].
    Uhl D
    Med Monatsschr Pharm; 1988 Nov; 11(11):376-8. PubMed ID: 3059163
    [No Abstract]   [Full Text] [Related]  

  • 10. The HIV vaccine pipeline, from preclinical to phase III.
    Schultz AM; Bradac JA
    AIDS; 2001; 15 Suppl 5():S147-58. PubMed ID: 11816163
    [No Abstract]   [Full Text] [Related]  

  • 11. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses.
    Didierlaurent A; Ramirez JC; Gherardi M; Zimmerli SC; Graf M; Orbea HA; Pantaleo G; Wagner R; Esteban M; Kraehenbuhl JP; Sirard JC
    Vaccine; 2004 Sep; 22(25-26):3395-403. PubMed ID: 15308364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experimental molecular design of recombinant vaccines].
    Lebedev LR; Goncharova EP; Sizov AA; Bulychev LE; Odegov AM; Ryzhikov AB
    Mol Biol (Mosk); 2003; 37(3):544-9. PubMed ID: 12815963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
    Bazhan SI; Belavin PA; Seregin SV; Danilyuk NK; Babkina IN; Karpenko LI; Nekrasova NA; Lebedev LR; Ignatyev GM; Agafonov AP; Poryvaeva VA; Aborneva IV; Ilyichev AA
    Vaccine; 2004 Apr; 22(13-14):1672-82. PubMed ID: 15068850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel vaccine delivery systems: solutions to HIV vaccine dilemmas?
    Sutter G; Haas J
    AIDS; 2001; 15 Suppl 5():S139-45. PubMed ID: 11816162
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R; Meyer D
    Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AIDS vaccine test to be expanded based on upbeat results.
    AIDS Read; 2005 Nov; 15(11):561, 573. PubMed ID: 16329176
    [No Abstract]   [Full Text] [Related]  

  • 18. Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy.
    Liu Z; Chen YH
    J Immunol Methods; 2004 Feb; 285(1):93-7. PubMed ID: 14871538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular construction of experimental combined vaccines].
    Lebedev LR; Sizov AA; Karpenko LI; Poryvaeva VA; Odegov AM
    Mol Gen Mikrobiol Virusol; 2002; (1):17-21. PubMed ID: 11904919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.